The Expanding Veterans' Access to Emerging Treatments Act directs the Veterans Affairs Department to establish a research program offering innovative treatments and emerging therapies—including psychedelic-assisted treatments like psilocybin and MDMA, as well as ketamine and other therapies—to veterans with conditions like chronic pain, PTSD, depression, and substance use disorders that currently lack effective treatments. The VA must designate a lead administrator within 60 days and develop the program within 90 days, creating both clinical trials and compassionate access pathways for eligible veterans. The department must report back within one year with information on participating clinics, the number of veterans involved, and findings on safety and efficacy, and the program will automatically be reviewed after two years for possible extension or termination. The bill does not specify new funding but allows the VA to use existing appropriations to support the research trials. This legislation aims to give veterans faster access to promising but still-investigational treatments for serious conditions while maintaining compliance with federal laws governing controlled substances and experimental drugs.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.